Nuvectis Pharma FY2028 EPS Forecast Lowered by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Research analysts at Roth Capital decreased their FY2028 EPS estimates for shares of Nuvectis Pharma in a research note issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $3.23 for the year, down from their prior estimate of $3.61. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s FY2029 earnings at $4.24 EPS.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08).

Separately, HC Wainwright reduced their price target on shares of Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday.

Nuvectis Pharma Stock Performance

Nuvectis Pharma stock opened at $6.69 on Thursday. The firm’s 50-day moving average is $6.26 and its 200-day moving average is $6.41. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $12.10. The company has a market cap of $129.26 million, a P/E ratio of -5.77 and a beta of 0.22.

Institutional Trading of Nuvectis Pharma

Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in Nuvectis Pharma during the 4th quarter valued at about $34,000. Nations Financial Group Inc. IA ADV acquired a new position in Nuvectis Pharma during the 3rd quarter valued at about $63,000. Baxter Bros Inc. increased its stake in Nuvectis Pharma by 20.0% during the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock valued at $81,000 after buying an additional 2,500 shares during the period. Squarepoint Ops LLC acquired a new position in Nuvectis Pharma during the 4th quarter valued at about $103,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Nuvectis Pharma during the 4th quarter valued at about $135,000. Institutional investors and hedge funds own 96.77% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were acquired at an average price of $5.00 per share, with a total value of $1,200,000.00. Following the acquisition, the insider now directly owns 2,884,121 shares in the company, valued at approximately $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought a total of 261,500 shares of company stock valued at $1,300,825 in the last quarter. Company insiders own 35.78% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.